Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

Fig. 1

Proportions of patients meeting criteria for the somatization comorbidity phenotype classification. Full analysis set. The denominator used to calculate the percentage for each category was based upon the total number of patients within the comorbidity/treatment assignment category; the sum of percentages was over 100% due to some patients taking more than one concomitant medication and/or possessing more than one medical diagnosis. aDefined as Anatomical Therapeutic Chemical Classification System (ATC) code N06AB. bDefined as ATC code M03BX. cDefined as ATC code N02BG. dIncluded medications in ATC codes N06AA (non-selective monoamine reuptake inhibitors), N06AX (other antidepressants), M03BA (carbamic acid esters), and M03BB (oxazol, thiazine, and triazine derivatives). SSRI selective serotonin reuptake inhibitors

Back to article page